NEW YORK, April 05, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) AXIM, a world leader in cannabinoid research and development, today announced that George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech, is scheduled to meet with business prospects and investors at BioCentury's annual Future Leaders in the Biotech Industry Conference on April 7, 2017 at the Millennium Broadway Hotel & Conference Center in New York City.
Now in its 24th year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
AXIM Biotech's presentation will be available on April 7th at this link.
About AXIM®
AXIM® Biotechnologies, Inc. AXIM focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Public Relations Contact Andrew Hard Chief Executive Officer CMW Media andrew.hard@cmwmedia.com P. +1888 829-0070 www.cmwmedia.com Investor Relations Contact Shiwei Yin, Grayling Shiwei.Yin@grayling.com P. +1646 284-9474 Lucia Domville, Grayling lucia.domville@grayling.com P. +1646 284-9416 Corporate Contact Info North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.